Last reviewed · How we verify

intermittent preventive treatment

London School of Hygiene and Tropical Medicine · Phase 2 active Small molecule

intermittent preventive treatment is a Small molecule drug developed by London School of Hygiene and Tropical Medicine. It is currently in Phase 2 development. Also known as: SP, Du-Cotecxin.

At a glance

Generic nameintermittent preventive treatment
Also known asSP, Du-Cotecxin
SponsorLondon School of Hygiene and Tropical Medicine
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about intermittent preventive treatment

What is intermittent preventive treatment?

intermittent preventive treatment is a Small molecule drug developed by London School of Hygiene and Tropical Medicine.

Who makes intermittent preventive treatment?

intermittent preventive treatment is developed by London School of Hygiene and Tropical Medicine (see full London School of Hygiene and Tropical Medicine pipeline at /company/london-school-of-hygiene-and-tropical-medicine).

Is intermittent preventive treatment also known as anything else?

intermittent preventive treatment is also known as SP, Du-Cotecxin.

What development phase is intermittent preventive treatment in?

intermittent preventive treatment is in Phase 2.

Related